Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1992;12:212-221

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mellott, M. J.
Right arrow Articles by Gardell, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mellott, M. J.
Right arrow Articles by Gardell, S. J.

Arteriosclerosis and Thrombosis, Vol 12, 212-221, Copyright © 1992 by American Heart Association

ARTICLES

Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis

MJ Mellott, II Stabilito, MA Holahan, GC Cuca, S Wang, P Li, JS Barrett, JJ Lynch and SJ Gardell
Department of Pharmacology, Merck Sharp & Dohme Research Laboratories, West Point, Pa 19486.

The efficacy of recombinant vampire bat salivary plasminogen activator (bat-PA) as a thrombolytic agent was compared with that of human tissue- type plasminogen activator (t-PA) in a canine model of arterial thrombosis. An occlusive thrombus was formed in the femoral artery by insertion of a thrombogenic copper coil; femoral arterial blood flow was monitored with a Doppler flow meter. Bat-PA and t-PA, when administered by 5-minute intravenous infusion (14 nmol/kg), reperfused seven out of eight and four out of eight dogs, respectively. The median reperfusion times in the bat-PA and t-PA groups were 24 and greater than or equal to 131 minutes, respectively. The mean reperfusion times (+/- SEM) in the recanalized bat-PA- and t-PA-treated dogs were similar (20 +/- 5 and 11 +/- 2 minutes, respectively, p = NS). Maximal blood flow after reperfusion was greater with bat-PA than with t-PA (80 +/- 10% and 41 +/- 15% of control flow, respectively, p less than 0.05). Furthermore, the median reocclusion time was markedly delayed in the bat-PA group relative to the t-PA group (131 versus 34 minutes, respectively, p less than 0.05). Plasma fibrinogen and plasminogen were not significantly depleted by the administration of t-PA or bat-PA. However, plasma alpha 2-antiplasmin activity was moderately depressed in the t-PA group relative to the bat-PA group (p less than 0.05). The clearance profile for t-PA was monoexponential, with a half-life (t1/2) of 2.4 +/- 0.3 minutes and a mean residence time of 3.5 +/- 0.4 minutes. The clearance profile for bat-PA was biexponential, with a t1/2 alpha of 0.9 +/- 0.2 minutes, a t1/2 beta of 20.2 +/- 2.7 minutes, and a mean residence time of 21.3 +/- 4.3 minutes. The steady-state volume of distribution displayed by bat-PA was 16-fold greater than that of t-PA. Zymography of serial plasma samples from the bat-PA- treated dogs failed to demonstrate the apparent generation of a complex between bat-PA and plasminogen activator inhibitor-1; the corresponding complex with t-PA was observed in plasma samples from the t-PA-treated dogs. The sustained recanalization and improved blood flow in the bat- PA group relative to the t-PA group and the avoidance of fibrinogenolysis by bat-PA, despite its prolonged mean residence time, suggest that bat-PA may be superior to t-PA as a thrombolytic agent.


This article has been cited by other articles:


Home page
 StrokeHome page
G. T. Liberatore, A. Samson, C. Bladin, W.-D. Schleuning, and R. L. Medcalf
Vampire Bat Salivary Plasminogen Activator (Desmoteplase): A Unique Fibrinolytic Enzyme That Does Not Promote Neurodegeneration
Stroke, February 1, 2003; 34(2): 537 - 543.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher
State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction
Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13.
[PDF]

Home page
 Eur Heart JHome page
F.J. Van de Werf
The ideal fibrinolytic: can drug design improve clinical results?
Eur. Heart J., October 2, 1999; 20(20): 1452 - 1458.
[PDF]

Home page
 J. Biol. Chem.Home page
P. Bringmann, D. Gruber, A. Liese, L. Toschi, Jör. Krätzschmar, W.-D. Schleuning, and P. Donner
Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators
J. Biol. Chem., October 27, 1995; 270(43): 25596 - 25603.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Montoney, S. J. Gardell, and V. J. Marder
Comparison of the Bleeding Potential of Vampire Bat Salivary Plasminogen Activator Versus Tissue Plasminogen Activator in an Experimental Rabbit Model
Circulation, March 1, 1995; 91(5): 1540 - 1544.
[Abstract] [Full Text]

Home page
 Toxicol PatholHome page
S. J. Gardell
The Search for the Ideal Thrombolytic Agent: Maximize the Benefit and Minimize the Risk
Toxicol Pathol, January 1, 1993; 21(2): 190 - 198.
[Abstract] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.